An observational study in Esophageal Cancer and Neoadjuvant Therapy, sponsored by Henan Cancer Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-20.
Sponsored by Henan Cancer Hospital · Observational
This study aims to predict the efficacy of different types of neoadjuvant therapy and related postoperative pathological indicators in patients with esophageal cancer based on imaging parameters from CT and multimodal MRI, as well as clinical indicators collected before and after neoadjuvant treatment.
1,593 studies on the registry are indexed under Esophageal Neoplasms; 461 are open to participants now.
This study's planned enrollment of 400 is above the median of 200 across 341 observational studies indexed under Esophageal Neoplasms.
Browse Esophageal Neoplasms studies →Henan Cancer Hospital is the lead sponsor of 228 studies on the registry; 130 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients were diagnosed with esophageal cancer by pathology at Zhengzhou University Affiliated Cancer Hospital from January 1, 2017 to December 31, 2024. Based on pre-treatment examinations such as endoscopic ultrasound, CT, MRI, and multidisciplinary consultation opinions, these patients underwent radical esophagectomy after receiving different kinds of neoadjuvant therapy.
Exclusion Criteria:
CT and multimodal MRI in prediction of neoadjuvant therapy efficacy and postoperative pathological indicators in esophageal cancer
To evaluate the effectiveness of CT and multimodal MRI in determining the neoadjuvant therapy efficacy and postoperative pathological indicators in esophageal cancer.
Time frame: March 2025 - January 2030
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Henan Cancer Hospital